会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Methods of selecting a dopaminergic neuron proliferative progenitor cells using Lrp4/Corin markers
    • 使用Lrp4 / Corin标记物选择多巴胺能神经元增殖祖细胞的方法
    • US08232052B2
    • 2012-07-31
    • US12868598
    • 2010-08-25
    • Yuichi OnoYasuko NakagawaYoshimasa Sakamoto
    • Yuichi OnoYasuko NakagawaYoshimasa Sakamoto
    • C12Q1/68
    • C12Q1/6883C12Q2600/158
    • In neuron transplantation therapy, in terms of safety, it is preferable to use a cell population consisting only of a desired type of cells, and to use postmitotic neurons in consideration to avoid the risk of tumorigenesis. Moreover, greater therapeutic effects would be expected through the use of earlier progenitor cells in consideration of post-transplantation viability, proper network formation ability, and such.According to the present invention, Lrp4, a gene that is specifically expressed in dopaminergic neuron proliferative progenitor cells prior to cell cycle exit, was identified. The use of Lrp4 expression in cells as an index allows for the isolation. of cells suitable for transplantation therapy of neurodegenerative diseases such as Parkinson's disease in terms of safety, survival rate, and network formation ability.
    • 在神经元移植治疗中,在安全性方面,优选使用仅由期望类型的细胞组成的细胞群,并考虑使用神经元神经元以避免肿瘤发生的风险。 此外,考虑到移植后的生存力,适当的网络形成能力等,通过使用较早的祖细胞可以预期更大的治疗效果。 根据本发明,鉴定了在细胞周期退出之前在多巴胺能神经元增殖祖细胞中特异性表达的基因Lrp4。 在细胞中使用Lrp4表达作为指标,可以进行分离。 的细胞在安全性,存活率和网络形成能力方面适用于帕金森病等神经变性疾病的移植治疗。
    • 4. 发明申请
    • Methods of Selecting a Dopaminergic Neuron Proliferative Progenitor Cells Using LRP4/CORIN Markers
    • 使用LRP4 / CORIN标记物选择多巴胺能神经元增殖祖细胞的方法
    • US20100323366A1
    • 2010-12-23
    • US12868598
    • 2010-08-25
    • Yuichi OnoYasuko NakagawaYoshimasa Sakamoto
    • Yuichi OnoYasuko NakagawaYoshimasa Sakamoto
    • C12Q1/68
    • C12Q1/6883C12Q2600/158
    • In neuron transplantation therapy, in terms of safety, it is preferable to use a cell population consisting only of a desired type of cells, and to use postmitotic neurons in consideration to avoid the risk of tumorigenesis. Moreover, greater therapeutic effects would be expected through the use of earlier progenitor cells in consideration of post-transplantation viability, proper network formation ability, and such.According to the present invention, Lrp4, a gene that is specifically expressed in dopaminergic neuron proliferative progenitor cells prior to cell cycle exit, was identified. The use of Lrp4 expression in cells as an index allows for the isolation. of cells suitable for transplantation therapy of neurodegenerative diseases such as Parkinson's disease in terms of safety, survival rate, and network formation ability.
    • 在神经元移植治疗中,在安全性方面,优选使用仅由期望类型的细胞组成的细胞群,并考虑使用神经元神经元以避免肿瘤发生的风险。 此外,考虑到移植后的生存力,适当的网络形成能力等,通过使用较早的祖细胞可以预期更大的治疗效果。 根据本发明,鉴定了在细胞周期退出之前在多巴胺能神经元增殖祖细胞中特异性表达的基因Lrp4。 在细胞中使用Lrp4表达作为指标,可以进行分离。 的细胞在安全性,存活率和网络形成能力方面适用于帕金森病等神经变性疾病的移植治疗。
    • 6. 发明申请
    • Lrp4/corin dopamine-producing neuron proliferation precursor cell marker
    • Lrp4 / corin多巴胺产生神经元增殖前体细胞标记
    • US20060240432A1
    • 2006-10-26
    • US10543003
    • 2004-01-23
    • Yuichi OnoYasuko NakagawaYoshimasa Sakamoto
    • Yuichi OnoYasuko NakagawaYoshimasa Sakamoto
    • C12Q1/68C12N5/08
    • C12Q1/6883C12Q2600/158
    • In neuron transplantation therapy, in terms of safety, it is preferable to use a cell population consisting only of a desired type of cells, and to use postmitotic neurons in consideration to avoid the risk of tumorigenesis. Moreover, greater therapeutic effects would be expected through the use of earlier progenitor cells in consideration of post-transplantation viability, proper network formation ability, and such. According to the present invention, Lrp4, a gene that is specifically expressed in dopaminergic neuron proliferative progenitor cells prior to cell cycle exit, was identified. The use of Lrp4 expression in cells as an index allows for the isolation. of cells suitable for transplantation therapy of neurodegenerative diseases such as Parkinson's disease in terms of safety, survival rate, and network formation ability.
    • 在神经元移植治疗中,在安全性方面,优选使用仅由期望类型的细胞组成的细胞群,并考虑使用神经元神经元以避免肿瘤发生的风险。 此外,考虑到移植后的生存力,适当的网络形成能力等,通过使用较早的祖细胞可以预期更大的治疗效果。 根据本发明,鉴定了在细胞周期退出之前在多巴胺能神经元增殖祖细胞中特异性表达的基因Lrp4。 在细胞中使用Lrp4表达作为指标,可以进行分离。 的细胞在安全性,存活率和网络形成能力方面适用于帕金森病等神经变性疾病的移植治疗。
    • 8. 发明申请
    • Lrp4/Corin DOPAMINERGIC NEURON PROLIFERATIVE PROGENITOR CELL MARKERS
    • Lrp4 / Corin DOPAMINERGIC神经元增殖型细胞标志物
    • US20080280301A1
    • 2008-11-13
    • US12110111
    • 2008-04-25
    • Yuichi OnoYasuko NakagawaYoshimasa Sakamoto
    • Yuichi OnoYasuko NakagawaYoshimasa Sakamoto
    • C12Q1/68
    • C12Q1/6883C12Q2600/158
    • In neuron transplantation therapy, in terms of safety, it is preferable to use a cell population consisting only of a desired type of cells, and to use postmitotic neurons in consideration to avoid the risk of tumorigenesis. Moreover, greater therapeutic effects would be expected through the use of earlier progenitor cells in consideration of post-transplantation viability, proper network formation ability, and such.According to the present invention, Lrp4, a gene that is specifically expressed in dopaminergic neuron proliferative progenitor cells prior to cell cycle exit, was identified. The use of Lrp4 expression in cells as an index allows for the isolation. of cells suitable for transplantation therapy of neurodegenerative diseases such as Parkinson's disease in terms of safety, survival rate, and network formation ability.
    • 在神经元移植治疗中,在安全性方面,优选使用仅由期望类型的细胞组成的细胞群,并考虑使用神经元神经元以避免肿瘤发生的风险。 此外,考虑到移植后的生存力,适当的网络形成能力等,通过使用较早的祖细胞可以预期更大的治疗效果。 根据本发明,鉴定了在细胞周期退出之前在多巴胺能神经元增殖祖细胞中特异性表达的基因Lrp4。 在细胞中使用Lrp4表达作为指标,可以进行分离。 的细胞在安全性,存活率和网络形成能力方面适用于帕金森病等神经变性疾病的移植治疗。
    • 10. 发明授权
    • Methods of selecting dopaminergic neuron proliferative progenitor cells using Lrp4/Corin markers
    • 使用Lrp4 / Corin标记物选择多巴胺能神经元增殖祖细胞的方法
    • US07807371B2
    • 2010-10-05
    • US12110111
    • 2008-04-25
    • Yuichi OnoYasuko NakagawaYoshimasa Sakamoto
    • Yuichi OnoYasuko NakagawaYoshimasa Sakamoto
    • C12Q1/68
    • C12Q1/6883C12Q2600/158
    • In neuron transplantation therapy, in terms of safety, it is preferable to use a cell population consisting only of a desired type of cells, and to use postmitotic neurons in consideration to avoid the risk of tumorigenesis. Moreover, greater therapeutic effects would be expected through the use of earlier progenitor cells in consideration of post-transplantation viability, proper network formation ability, and such.According to the present invention, Lrp4, a gene that is specifically expressed in dopaminergic neuron proliferative progenitor cells prior to cell cycle exit, was identified. The use of Lrp4 expression in cells as an index allows for the isolation. of cells suitable for transplantation therapy of neurodegenerative diseases such as Parkinson's disease in terms of safety, survival rate, and network formation ability.
    • 在神经元移植治疗中,在安全性方面,优选使用仅由期望类型的细胞组成的细胞群,并考虑使用神经元神经元以避免肿瘤发生的风险。 此外,考虑到移植后的生存力,适当的网络形成能力等,通过使用较早的祖细胞可以预期更大的治疗效果。 根据本发明,鉴定了在细胞周期退出之前在多巴胺能神经元增殖祖细胞中特异性表达的基因Lrp4。 在细胞中使用Lrp4表达作为指标,可以进行分离。 的细胞在安全性,存活率和网络形成能力方面适用于帕金森病等神经变性疾病的移植治疗。